Results 11 to 20 of about 76,979 (321)

Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines

Human Vaccines & Immunotherapeutics, 2021
The universal administration of pneumococcal conjugate vaccines (PCVs) had been demonstrated as an effective way to prevent Streptococcus pneumoniae infection.
Qian-qian Du, Wei Shi, Dan Yu, Kai-hu Yao   +3 more
doaj   +2 more sources

Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience

Expert Review of Vaccines, 2018
Introduction: Pneumococcal diseases (including septicemia, meningitis, pneumonia, and upper respiratory infections) constitute a major public health problem.
Tomas Mrkvan, Stephen I. Pelton, Javier Ruiz-Guiñazú, Arto A. Palmu, Dorota Borys   +4 more
doaj   +2 more sources

Strengths and weaknesses of pneumococcal conjugate vaccines

Glycoconjugate Journal, 2023
AbstractMultivalent vaccines addressing an increasing number of Streptococcus pneumoniae types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite the emergence of non-vaccine serotypes ...
Micoli, Francesca, Romano, Maria Rosaria, Carboni, Filippo, Adamo, Roberto, Berti, Francesco   +4 more
openaire   +3 more sources

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

MMWR. Morbidity and mortality weekly report, 2022
In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years ...
Miwako Kobayashi, Jennifer L. Farrar, R. Gierke, Amadea Britton, L. Childs, A. Leidner, D. Campos-Outcalt, Rebecca L Morgan, Sarah S. Long, H. Talbot, K. Poehling, T. Pilishvili   +11 more
semanticscholar   +1 more source

Development of a pneumococcal conjugate vaccine [PDF]

Paediatrics & Child Health, 2001
George R. Siber
openaire   +3 more sources

Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

MMWR. Morbidity and mortality weekly report, 2022
The 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Merck Sharp & Dohme LLC]) have been recommended for U.S.
Miwako Kobayashi, Jennifer L. Farrar, R. Gierke, A. Leidner, D. Campos-Outcalt, Rebecca L Morgan, S. Long, K. Poehling, A. Cohen, K. Poehling, S. Long, J. Kelman, Lucia Lee, Tina Mongeau, T. Weiser, Uzo Chukwuma, Kristina Lu, M. Makhene, Lynn Fisher, Mark Sawyer, Jason Goldman, D. Nace, Emily Messerli, Elissa Abrams, Aleksandra K. Wierzbowski, Carol Baker, James McAuley, W. Schaffner, Virginia Cane, D. Campos-Outcalt, M. Farley, K. Klugman, Rebecca L Morgan, A. Reingold, L. Rubin, C. Whitney, R. Zimmerman, Emma K. Accorsi, Alison P. Albert, Shriya Bhatnagar, L. Childs, M. Fischer, R. Gorwitz, Angela J. Jiles, Heidi L Moline, P. Moro, Chukwuebuka Nsofor, N. Prasad, H. Walker, Jacquline Risalvato, S. Schillie   +50 more
semanticscholar   +1 more source

Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine

JAMA Network Open, 2022
This cohort study estimates the association between vaccination with 13-valent pneumococcal conjugate vaccine and hospitalizations for all-cause pneumonia and lower respiratory tract infection among older adults in a large health care system in ...
Amber Hsiao, John Hansen, Julius Timbol, N. Lewis, R. Isturiz, Ronika Alexander-Parrish, John M. McLaughlin, Bradford D. Gessner, Nicola P. Klein   +8 more
semanticscholar   +1 more source

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

Clinical Infectious Diseases, 2021
Background Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease, but disease from non-PCV serotypes remains. The safety, tolerability, and immunogenicity of a 20-valent PCV (PCV20) were evaluated.
B. Essink, Charu Sabharwal, Kevin P. Cannon, R. Frenck, Himal Lal, Xia Xu, V. Sundaraiyer, Yahong Peng, Lisa Moyer, M. Pride, Ingrid L Scully, K. Jansen, W. Gruber, D. Scott, W. Watson   +14 more
semanticscholar   +1 more source

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.

PLoS ONE, 2022
Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes.
Sweta M Patel, Yazdani B Shaik-Dasthagirisaheb, Morgan Congdon, Rebecca R Young, Mohamed Z Patel, Tiny Mazhani, Sefelani Boiditswe, Tirayaone Leburu, Kwana Lechiile, Tonya Arscott-Mills, Andrew P Steenhoff, Kristen A Feemster, Samir S Shah, Coleen K Cunningham, Stephen I Pelton, Matthew S Kelly   +15 more
doaj   +3 more sources

Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients

Transplantation Direct, 2020
Background. Pneumococcal conjugate vaccination as well as pneumococcal polysaccharide vaccination are recommended for lung transplant candidates and recipients, but the combination of these vaccines has not been extensively studied in these specific ...
Thijs W. Hoffman, MD, Bob Meek, PhD, Ger T. Rijkers, PhD, Jan C. Grutters, MD, PhD, Diana A. van Kessel, MD, PhD   +4 more
doaj   +1 more source